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Gestational diabetes is defined as impaired glucose tolerance with onset during 
pregnancy and affects approximately 8.2% of pregnancies. Recently, it has been shown 
that insulin resistance is a predictor of poor milk supply in women attempting to 
breastfeed. Some mothers with gestational diabetes who used metformin for optimal 
glycemic control during pregnancy have found that metformin use has improved their 
ability to produce milk after delivery; however, the effects of continuing metformin 
postpartum have not yet been studied. It is theorized that continued metformin use in the 
postpartum period in women with gestational diabetes may improve postpartum milk 
production. Using a randomized control trial, our objective is to determine if 
continuing the use of metformin for 8 weeks postpartum is an effective intervention 
in increasing milk supply in women who are diagnosed with gestational diabetes. We 












CHAPTER 1: INTRODUCTION 
1.1 Background 
 
1.1.1 The Burden of Gestational Diabetes Mellitus 
Gestational diabetes mellitus (GDM) is one of the most common medical 
complications of pregnancy and has important health implications for both the mother 
and child even after pregnancy. In recent years, studies have shown that the rate of 
mothers being diagnosed with GDM has significantly increased therefore making it an 
important public health concern to address. In one study from 2016 it was estimated that 
the prevalence of GDM increased to 8.2% from 4.6% in 2010. 1   
Gestational diabetes mellitus is defined as impaired glucose tolerance with onset, 
or first recognition, during pregnancy. 2 Insulin resistance during pregnancy stems from a 
variety of factors, one being the secretion of human placental lactogen which is a 
hormone that is produced and secreted by the placenta. This hormone functions in 
breaking down fats from the mother in order to provide carbohydrates for the baby in the 
placenta.3 Additionally, it creates a state of mild insulin resistance for the mother in order 
to benefit the fetus by increasing the availability of maternal glucose for fetal 
consumption.4 Normally, the beta cells of the pancreas are able to make additional insulin 
to overcome this insulin resistance, but when the production of insulin is not enough to 
overcome the effects of the placental hormones, the result is gestational diabetes. 
Routine screening for GDM is typically performed been 24 and 28 weeks of 




screen and then a diagnostic test. The first test is known as the oral glucose challenge test 
(GCT).5 This test involves drinking a solution containing 50g of glucose and drawing 
blood to measure glucose levels at one hour after consumption. If positive, women then 
are asked to complete a fasting 3-hour oral glucose challenge test (OGTT) with 100g of 
glucose in solution and have their glucose levels checked fasting and at 1, 2, and 3 hours 
after consumption of the drink. There are two subtypes of gestational diabetes that are 
classified using the White classification system, they are type A1 and type A2.3 A patient 
is diagnosed with type A1 GDM if they are able to keep their blood sugars at goal with 
diet and exercise alone. A diagnosis of type A2 GDM is made when a patient has GDM 
and has blood glucose values above target for fasting and after meals.  This type of GDM 
requires more aggressive treatment with insulin or other medications.3   
Gestational diabetes increases the risk of complications in pregnancy and 
childbirth as well as long-term health for the mother and infant. GDM carries a long-term 
risk of obesity and glucose intolerance in the offspring. One of the best interventions 
proven to help reduce obesity in children is through breastfeeding, which is 
recommended for the first six months of life according to the American Academy of 
Pediatrics.6 However, only about 19% of women who initiate breastfeeding do so for the 
entire six months.7 One of the biggest reasons that is given as to why many women stop 
breastfeeding earlier than they intended to is because of a low milk supply. Other than 
encouraging mothers to increase the frequency and thoroughness of breast emptying, 




 Emerging evidence suggests that glucose intolerance and delayed lactogenesis are 
correlated and that diabetes during pregnancy may increase the risk of persistent low milk 
supply. In a case-control analysis, Riddle et al. 2016 showed that women who were 
diagnosed with a low milk supply were significantly more likely to also have been 
diagnosed with GDM and have problems with insulin metabolism compared to other 
mothers.7 It has also been shown that lactation onset is delayed in obese women with 
poor glucose control.9 The onset of lactation plays a crucial role in the duration of 
breastfeeding as seen in a recent study by Chapman et al.10 This study additionally 
showed that on average women who experienced delayed onset of lactation breastfed for 
a much shorter duration.  
Over time we have started to better understand that insulin plays a role in lactation 
and that impaired insulin and glucose metabolism is correlated with poor lactation in 
mothers. A recent study showed that insulin stimulates the expression of genes that are 
directly involved in milk protein synthesis.11 Since proper insulin levels are necessary for 
lactation, good glycemic control can enhance milk production while decreasing the delay 
in lactation.12 We hypothesize that by continuing metformin postpartum in women who 
were diagnosed with GDM and continuing to control glucose and insulin levels, we may 
see an increase in breast milk production as well as a more rapid onset of lactation.  
1.1.2 Role of Metformin Use in Gestational Diabetes Mellitus  
 
It has been shown that with proper treatment of GDM the incidence of many of 
the adverse complications associated with GDM can be reduced. Nutritional management 
and exercise are the foundations of treatment, but insulin or metformin are added in 




alone. Although insulin has been and still is considered the gold standard therapy of 
choice during pregnancy for many decades, oral hypoglycemic medications have recently 
been introduced as treatment for GDM as many women find the prospect of multiple 
injections a day intolerable.13  
One specific oral antidiabetic medication is metformin. This drug has been used 
for decades in the treatment of type 2 diabetes as well as polycystic ovarian syndrome but 
its use in pregnancy has be limited.14 Recently, several observational and randomized 
control trials compared metformin to insulin and have found that metformin does not 
increase adverse outcomes, and potentially even reduces maternal weight gain during 
pregnancy, which is key in this population as many enter pregnancy with elevated 
BMIs.15 Metformin has several mechanisms of action which include, decreasing hepatic 
glucose production by suppressing gluconeogenesis, increasing insulin sensitivity, as well 
as enhancing peripheral glucose uptake.14,16 All of these functions lead to lower blood 
glucose levels and improved glycemic control.17 Since it is recently starting to be 
understood that insulin plays a role in lactation and that impaired insulin and glucose 
metabolism is correlated with poor lactation in mothers, we believe that by continuing 
metformin during the postpartum period and continuing to control glucose levels, we 
could see an increase in breast milk production as well as a more rapid onset of lactation.  
In all of the studies that have addressed the different therapeutic options for 
diabetes during pregnancy several neonatal and maternal outcomes have been analyzed 
and studied but one factor that has not been studied in depth is the effect on breast milk 
production and lactogenesis. Breastfeeding is an important factor that is known to impact 




study, especially in correlation with metformin therapy. It has been shown that delayed 
onset of lactation and the perception of having a poor breastmilk supply is associated 
with a shorter breastfeeding duration.10,18 Therefore, finding a way to increase the 
postpartum milk production in women diagnosed with GDM could aid in longer 
compliance with breastfeeding.  
1.2 Statement of the Problem  
For many years, it has been known that maternal obesity is associated with 
delayed lactogenesis and a shortened duration of breastfeeding.19 Recently a study known 
as the Feeding Practices Study II showed that “insufficient milk” was the primary factor 
that mediated the association between maternal obesity and lower prevalence of exclusive 
breastfeeding.20 We know that insulin resistance plays a huge role in obesity but for many 
years it was believed that insulin did not play a direct role in mammary gland function. 
Recently, studies have shown mammary glands to be sensitive to insulin during 
pregnancy and lactation.21 This leads us to believe that mothers with insulin-resistant 
conditions, such as gestational diabetes, are at an increased risk for insufficient milk 
production.  
Metformin is a first line drug for improving insulin sensitivity, and it is known to 
be safe for use during lactation through studies of women with Type 2 diabetes;22 
however, its efficacy in improving milk production has not yet been studied, specifically 
when continuing treatment with metformin into the postpartum period in women 
diagnosed with gestational diabetes and treated with metformin during pregnancy. This 
supports the need for a randomized control trial to investigate the effects of metformin on 




breastfeeding in mothers with gestational diabetes. It is relevant to medical practice, 
specifically physician assistant practices, because it would aid in understanding how to 
best treat mothers with gestational diabetes in the postpartum period and how to help 
them reach their breastfeeding goals, which could in turn improve long-term health 
outcomes for themselves as well as their children.  
1.3 Goals and Objectives 
This study aims to investigate the relationship between postpartum metformin use 
and breastmilk production in women who were diagnosed with A2 gestational diabetes 
and treated with metformin during pregnancy. We want to determine if metformin use 
has an effect on the mammary glands and therefore milk production.   
Our primary outcome will be breastmilk production which will be measured using 
infant test weighs taken immediately before and after each feeding. This will be 
statistically analyzed as a continuous variable. Secondary outcomes that will be measured 
include the following: maternal fasting blood glucose levels, infant weight gain over the 
course of the study period at office visits, number of wet diapers per day, and need for 
supplementation with formula as prescribed by a pediatrician due to poor weight gain. 
We have chosen these secondary variables because they are significant, independent 
factors that may be predictors of how well our independent variable, metformin, is 
functioning and the effects that it is producing in addition to how it affects maternal 
glycemic control in the postpartum period. These outcomes will allow us to explore the 
potential beneficial effects of metformin as an intervention on low milk supply in 




1.4 Hypothesis  
We hypothesize that continuing metformin treatment for 8 weeks postpartum in women 
who are diagnosed with gestational diabetes mellitus will lead to an increase in 
breastmilk production through better glucose control. 
1.5 Definitions  
• Blood Glucose Levels: The concentration of glucose present in the blood. 
Measured with a sample of blood. A fasting blood glucose level under 100mg/dL 
is normal in non-pregnant individuals.   
• Gestational Diabetes Mellitus: Gestational diabetes mellitus (GDM) occurs when 
a woman’s pancreatic function is not sufficient to overcome the diabetogenic 
environment of pregnancy. GDM is defined as glucose intolerance that was not 
present or recognized prior to pregnancy.3 
• Insulin: A hormone made by the pancreas that allows your body to use sugar 
(glucose) from carbohydrates in the food that you eat for energy or to store 
glucose for future use. Insulin helps to prevent blood sugar level from getting too 
high or too low. 
• Lactogenesis: The onset of milk secretion and includes all of the changes in the 
mammary epithelium necessary to go from the undifferentiated mammary gland 
in early pregnancy to full lactation.23 




• Postpartum: The period of time that begins immediately after the birth of a child 
as the mother’s body returns to a non-pregnant state. In this study we refer to the 
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 We conducted multiple searches of medical literature databases, including 
PubMed, Ovid, and Cochrane, starting in August 2019 through July 2020. In these 
searches, we used the MeSH terms [gestational diabetes] or [insulin resistance, 
pregnancy-induced] and [metformin] or [hypoglycemic drugs] and [breast feeding] or 
[lactation] or [human milk] or [milk supply]. We further reviewed the references of these 
studies to identify relevant studies not found in our searches. We included mostly 
systematic reviews, meta-analyses, and quantitative studies, including case-control 
studies, cohorts, and randomized controlled trials.  
2.2 Review of Empirical Studies   
 
2.2.1 Gestational Diabetes Mellitus  
 
 Gestational diabetes mellitus (GDM), the most common metabolic disorder of 
pregnancy, is defined as “the type of glucose intolerance that develops in the second and 
third trimester of pregnancy, resulting in hyperglycemia of variable severity”1. 
Gestational diabetes mellitus affects approximately 8.2% of pregnancies in the United 
States, and it is increasing in prevalence as a consequence of increases in obesity 
prevalence and advanced maternal age.2 Gestational diabetes mellitus occurs when a 
mother develops dysglycemia because of endocrine disruption that occurs during 
pregnancy. Insulin resistance during pregnancy stems from a variety of factors, one being 
the secretion of human placental lactogen which is a hormone that is produced and 
secreted by the placenta. This hormone functions in breaking down fats from the mother 




mild insulin resistance for the mother in order to benefit the fetus by increasing the 
availability of maternal glucose for fetal consumption.4 Normally, the beta cells of the 
pancreas are able to make additional insulin to overcome this insulin resistance, but when 
the production is insulin is not enough to overcome the effects of the placental hormones, 
the result is gestational diabetes.  
There are two different subtypes of gestational diabetes based on the White 
Classification system; A1 and A2. They differ in the forms of treatment that they require. 
Type A1 is able to be adequately controlled with diet and exercise whereas type A2 
requires more intensive treatment with medications.5 Screening for GDM usually occurs 
between 24 and 28 weeks of gestation6 and is typically done by utilizing the two step 
approach. The first is a screening involving a 50g oral glucose challenge test, where the 
mother drinks a beverage consisting of 50 grams of dissolved sugar and an hour later her 
blood is drawn to measure the glucose concentration.6 If the value is less than 130-140 
(depending on the lab and cut-off used) then the test is said to be normal, but if the blood 
sugar levels are elevated then further testing must be conducted to diagnose gestational 
diabetes.7 The subsequent diagnostic test to be performed is the glucose tolerance test 
which must be done after the conclusion of an eight-hour fast by the patient. A fasting 
sample of blood is taken first, typically first thing in the morning, and then the patient 
drinks a beverage that contains 100 grams of glucose. Blood samples are then taken after 
1, 2 and 3 hours.6 If two of the four blood sugar values are elevated the mother is then 




Once the diagnosis is made it is important to determine the best treatment plan 
due to the risk of complications that are associated with it. The initial treatment of GDM 
consists of diet modifications, glucose monitoring, and exercise. 9 If these measures fail 
to adequately control blood sugar, medications such as insulin or metformin are used to 
achieve euglycemia.6 Initiation of treatment in mothers with GDM is important because it 
has been shown to reduce the rate of serious neonatal outcomes such as death, large for 
gestational age infants, shoulder dystocia, bone fractures and nerve palsy.10 
2.2.2 Treatment of Gestational Diabetes Mellitus 
Insulin, for many years, has been the treatment of choice when lifestyle changes 
fail to maintain proper glycemic control during pregnancy. 9 Recently studies have 
suggested that oral hypoglycemic medications may be safe and acceptable alternatives, 
one specific medication being metformin.11 Metformin was first approved for the 
treatment of diabetes in the United States by the FDA in 1995 and has been used for 
decades in the treatment of type 2 diabetes as well as polycystic ovarian syndrome but its 
use in pregnancy has be limited.12 Metformin is a biguanide and has several mechanisms 
of action which include, decreasing hepatic glucose production by suppressing 
gluconeogenesis, increasing insulin sensitivity, as well as enhancing peripheral glucose 
uptake.12 All of these functions lead to lower blood glucose levels and better glucose 
control. Studies has shown that metformin can achieve blood glucose control in women 
with GDM just as effectively as insulin but at a lower cost and with better adherence due 
to it being an oral medication rather than one that must be injected.13 Additionally, one 
randomized control trial known as the Metformin in Gestational Diabetes Trial which 




women with GDM and found that metformin does not increase adverse outcomes and 
may even reduce maternal weight gain during pregnancy.14 This was one of the largest 
studies that aided in introducing metformin as an alternative treatment for GDM. When 
treating women with gestational diabetes metformin can be initiated from the time of 
diagnosis and is typically discontinued with delivery.  
Although the standard therapy for women with gestational diabetes requiring drug 
treatment has been insulin for many years, in some settings oral agents are now becoming 
the first option.15 Metformin treatment is usually initiated with divided doses of 500mg 
twice a day and the dose can be increased up to 2000mg daily.16 Oral agents are 
becoming an attractive alternative to insulin due to their lower cost, easier administration 
and better acceptance by patients compared to injections with insulin. 
2.2.3 Benefits of Breastfeeding 
 
Breastfeeding has many health benefits, both in the short term and long term for 
both infants and their mothers. Due to ethical considerations it is difficult to perform 
randomized control trials looking at the benefits of breastfeeding, but there have been 
many observational studies that have carefully analyzed the relationship between 
breastfeeding and maternal and infant outcomes. Research suggests there are particular 
benefits of breastfeeding for women with a history of GDM and their infants,17 including 
improved short-term insulin sensitivity and glucose homeostasis,18 improved long-term 
insulin sensitivity,19 and reduced risk of type 2 diabetes20 many years postpartum. 
Specifically, it was shown that women with GDM who breastfed for at least 3 months 




reported a protective association between breastfeeding and type 2 diabetes risk22,23 and 
slower early weight gain24 among offspring of women with GDM. A systemic review by 
the World Health Organization found that breastfed infants were 35% less likely to 
develop subsequent type 2 diabetes compared to their non-breastfed 
counterparts.25Despite established benefits of breastfeeding, there is evidence that 
breastfeeding initiation, duration, and exclusivity may be lower among women with 
GDM26-28   
2.2.4 Relationship between Metabolic Disorders and Lactation  
 
It is well established that obese women are at increased risk of delayed 
lactogenesis and short breastfeeding duration, but the underlying causal contributors 
remain unclear.29 Maternal obesity is a strong risk factor for insulin resistance and 
prediabetes, but until recently a direct role for insulin in milk production had not been 
elucidated. Over the past six years, studies in both animal models and humans have 
shown insulin-sensitive gene expression to be dramatically upregulated specifically 
during the lactation cycle. Insulin is now considered to play a direct role in lactation, 
including essential roles in secretory differentiation, secretory activation, and mature milk 
production. At the same time, emerging clinical research suggests an important 
association between suboptimal glucose tolerance and lactation difficulty. To develop 
effective interventions to support lactation success in obese women further research is 
needed to identify how, when, and for whom maternal insulin secretion and sensitivity 
affect lactation ability. 
Recently there has been emerging evidence that suggests that glucose intolerance 




the risk of persistent low milk supply. In a case-control analysis it was shown that women 
who were diagnosed with a low milk supply were significantly more likely to also have 
been diagnosed with GDM. Specifically, they were found to be 2.6 times more likely to 
have problems with insulin metabolism compared to other mothers.30 It has also been 
shown that lactation onset is delayed in women with poor glucose control. The onset of 
lactation plays a crucial role in the duration of breastfeeding as seen in a recent study by 
Chapman et al.31 This studied showed that on average women who experienced delayed 
onset of lactation, >72 hours after delivery, on average breastfed for 8 months less than 
mothers who experienced lactation within 72 hours of delivery.  
Although it’s been shown in studies that all women with GDM have lower 
exclusive breastfeeding rates compared to women without GDM, one study which looked 
at metformin versus placebo in postpartum women with GDM found that women who 
had been randomized to the metformin group had a higher exclusive breastfeeding rate 
compared to placebo, 22.2% versus 9.3%, p=0.055.32 This same study also found that the 
frequency of breastfeeding cessation was lower in the metformin group compared to 
placebo, 21.9% vs. 36.8%, p=0.912. In numerous studies it is frequently cited that low 
milk supply is the reason why many mothers stop breastfeeding earlier than they had 
planned.33 Riddle and Nommsen-Rivers (2016) conducted a case control study to better 
understand the relationship between maternal diabetes and low milk supply, this was the 
first study conducted to look at this relationship. The study found that the presence of 
diabetes during pregnancy increased the risk of persistent low milk supply. Mothers with 
a diagnosis of low milk supply but no other lactation problems, such as latching onto the 




In the case group 14.9% of the women had a history of diabetes during pregnancy, while 
in the control group 6.2% of the women who had lactation problems but not low milk 
supply had maternal diabetes.30 
Since low milk supply appears to be associated with gestational diabetes this 
could support the concept that interventions targeting insulin action and glycemic control 
may be a promising and novel strategy toward improving milk supply in vulnerable 
mothers. 
2.2.5 Breastfeeding Outcomes and Gestational Diabetes Mellitus 
Studies of gestational diabetes mellitus in relation to breastfeeding are limited in 
number but the majority suggest the same outcomes, that breastfeeding issues are higher 
in mothers with GDM compared to mothers without GDM. These studies cite problems 
such as delayed onset of lactation, lower breastmilk production and shorter breastfeeding 
duration as some of the adverse outcomes from having GDM.30,31 Infants born to mothers 
with GDM are more likely to experience complications, such as cesarean delivery, 
preterm birth and macrosomia, and therefore require intensive care. All of these factors 
also result in lower breastfeeding rates.34 In a U.S. study, women with GDM were about 
40% less likely to be exclusively breastfeeding on hospital discharge compared women 
without diabetes.27  In another study that covered 37 states in the United States, the 
initiation rates were similar between mothers with and without GDM, but the mothers 
with GDM tended to cease breastfeeding earlier: 65.7% vs 68.8% at 2 months 
postpartum, respectively.35 Factors that may affect the disparity include physiologic and 
behavioral challenges like higher prevalence of delayed onset of lactation,36,37 neonatal 




Identification of a lower breastfeeding rate in a population that benefits more from 
breastfeeding is what has motivated us to develop this research question to identify the 
barriers that contribute to decreased breastfeeding in women with GDM. We hope to use 
this study to determine proper methods and therapies to help combat these impediments 
to breastfeeding. Additionally, we recognize the need to perform this study in a racially 
and ethnically diverse population as these are populations with lower breastfeeding rates 
and with higher risk for GDM.  
2.3 Confounding Variables 
 It is difficult to isolate the effect of metformin on breastmilk production due to a 
multitude of potential confounding variables. These include maternal age, maternal 
ethnicity, maternal marital status, pre-pregnancy BMI, family history of GDM or type 2 
diabetes, diagnosis of GDM in previous pregnancies, other signs of insulin resistance 
such as polycystic ovarian syndrome or metabolic syndrome, number of previous 
breastfed infants, vaginal versus cesarean delivery, gestational age at delivery, previous 
breast surgery, maternal education level, maternal socioeconomic status and parity. The 
majority of these will be discussed in this section.  
Pre-pregnancy BMI is often controlled for in statistical analyses as a covariate in 
studies that analyze the effect of GDM on breastfeeding.29 Most of these studies have 
even found that pre-pregnancy BMI significantly affect their results.21,29.  In a study 
conducted by Pinhero et al, it was found that women who had a higher pre-pregnancy 
BMI in addition to GDM had a much higher likelihood of having delayed breastfeeding 
initiation compared to those mothers who had a normal pre-pregnancy BMI and GDM. 




exclusive breastfeeding at time of discharge found that women with a higher pre-
pregnancy BMI compared to women with a normal pre-pregnancy BMI had lower odds 
of exclusively breastfeeding at the time of discharge.27 This study also showed us that the 
presence of GDM was negatively associated with higher a BMI.27 Together, these two 
previous studies show that pre-pregnancy BMI should be considered as a potential 
confounder in the present study. 
Several studies have identified maternal characteristics such as younger maternal 
age, low income, ethnicity, less maternal education, and unmarried status to be associated 
with lower breastfeeding prevalence among women so these will all be taken into 
consideration as confounders as well.40,41 Additionally, research studies conducted by 
Ahluwalia et al indicated that women who had induced labor or cesarean sections were 
less likely to initiate and continue breastfeeding compared to women who had 
spontaneous vaginal deliveries.42,43 Due to this information we will also consider the 
different types of delivery, vaginal vs cesarean, to be a confounders in our proposed 
study.  
In the proposed study, randomization will act to minimize any statistically 
significant differences in baseline characteristics between the control and intervention 
groups, which will serve to minimize the effects of confounding on the results. 
Furthermore, we plan to collect and report these characteristics and will note any 
significant differences in baseline characteristics between groups.  
2.4 Safety 
Metformin is a first-line, FDA approved drug for treating Type 2 diabetes.44 In 




syndrome to improve insulin action.45 More recently studies have been conducted 
showing that it is safe to use during lactation with milk concentrations being very low 
and serum concentrations in breastfed infants being nearly undetectable.46 A large 
prospective study by Glueck et al found that there were no adverse effects or differences 
in growth and development between infants who were breastfed vs formula fed of 
mothers that were taking metformin for 6 months postpartum.47 One of the most 
concerning side effects of metformin is lactic acidosis. However, in a review of 18 
clinical studies that looked at the use of metformin for treatment of polycystic ovary 
syndrome there were not any reports of lactic acidosis occurring.45 All of this supports 
the safety of metformin use in our study in both women with GDM and their infants and 
we do not expect to see any negative effects on neonatal or maternal outcomes.  
2.5 Review of Relevant Methodology 
The purpose of this section is to review methodology in previous studies as they 
pertain to the proposed study. A detailed description of the proposed study’s methods will 
be discussed in Chapter 3.   
2.5.1 Study Design  
Most previous studies examining the effect of gestational diabetes on breastmilk 
supply and lactation have been retrospective cohort studies, prospective cohort studies or 
case-control studies.29,30,48 These designs of studies are limited since they can only 
establish an association between GDM and low breastmilk supply, they can’t explain the 
mechanism behind the outcome or establish direct correlation between metformin use 
postpartum and breastfeeding in women with A2GDM during pregnancy. Thus, the 




causal relationship between the intervention and the primary outcome while minimizing 
the effect of bias and confounding variables.  
Due to the nature of the intervention we will be able to blind the participants to 
the group they are randomized to by giving the control group a placebo. In the 
randomized controlled trial conducted by Nommsen-Rivers et al, the authors blinded the 
members of the research team, as well as the statistician who reviewed the data that was 
collected, to the allocation.49 We will similarly blind the research team members who 
review the medical charts and data in order to reduce bias effect on the investigators’ 
interpretation of the results.  
2.5.2 Selection Criteria  
In order to select the inclusion and exclusion criteria for the proposed study, we 
analyzed several previous studies’ selection criteria and chose the most applicable and 
relevant to our study population.   
First, our study will include only women with a diagnosis of GDM type A2 
treated with metformin during pregnancy as this is the intended study population. We 
differentiated type A1 from A2 because our study participants will have received treated 
with metformin to control their blood glucose levels during the antenatal period. This 
means that the participants will have GDM that didn’t respond to diet and exercise 
changes alone and therefore need additional treatment with metformin. The gestational 
age at time of recruitment in a previous randomized controlled trial was more than or 
equal to 37 weeks’ gestation but in that study the intervention was started after birth.49 
For the sake of our proposed study, we will only include term deliveries which means any 




will be recruited. The study will be introduced at the time of their diagnosis of GDM 
requiring metformin for glycemic control during pregnancy, which could occur as early 
as 24 weeks gestation. Consent and randomization will occur at the clinic once women 
have reached 37 weeks’ gestation to ensure they were maintained on metformin for 
glycemic control with their A2GDM diagnosis. 
For our study, it is important to ensure that our group of women doesn’t have any 
complicating comorbidities or prior diagnosis of diabetes that could alter our outcome 
data. For similar reasons, Nommsen-Rivers et al excluded women who were diagnosed 
pre-gestational Type 1 or Type 2 diabetes as well as those who had a history of breast 
surgery and we will do the same in our study.49 Multiple gestation is defined as a high-
risk pregnancy that increases the likelihood of GDM. Because of this, Nommsen-Rivers 
et al excluded women with multiple gestation and we will also exclude women with 
multiple gestations.   
Furthermore, it is important to our study that participants are able to engage in 
frequent and exclusive breastfeeding regardless of which group they are randomized to. 
When conducting their study with breast pumping and breast emptying, Nommsen-Rivers 
et al excluded women who would have insufficient frequency of completing both 
pumping and emptying.49 In the proposed study, we will exclude women who do not plan 
to exclusively breastfeed.  
2.5.3 Intervention  
In the previous RCT conducted by Nommsen-Rivers et al participants were 
randomized 2:1 metformin:placebo allocation for the purpose of gathering more insight 




allocating participants in a 1:1 scheme. As was done in previous studies, we will be 
encapsulating the metformin and the placebo into matching capsules and packages for the 
purpose of maintaining blinding as best as we can. Unlike previous studies where the 
intervention was started at the time of birth and given in accordance with a titration 
schedule,49 our study will allow participants to remain on the same dose postpartum as 
they were on in the antenatal period. To collect the data needed for the secondary 
outcomes, participants will be given journals with specific forms to be filled out daily 
over the course of the study. 
2.5.4 Primary and Secondary Outcome Measures 
A common problem encountered in studies on breastfeeding is how to quantify 
the amount of breastmilk produced. The primary outcome for relevant studies is milk 
output and this has been measured through weighing all milk that has been expressed and 
collected over a 24 hour period.49 We felt that this data collection method was not 
feasible for new mothers since it required extensive time and effort and therefore we 
wouldn’t have good compliance among study participants. Instead, we plan to collect our 
data using test weighs in which the participants will weight their infant on a specialized 
scale provided to them immediately before and after each feeding. There have been many 
studies conducted in the past that have concluded that test weighing is a reliable method 
for assessing milk intake in infants 50-53 so we feel as though this will still provide us with 
accurate data while making it as feasible as possible for our study participants. 
 Maternal fasting blood glucose levels and neonatal weights are often secondary 
outcomes in previous studies examining the effect of metformin treatment in women with 




examine the mother’s glucose levels as a secondary outcome as well as trend the infant’s 
weight over the course of the study. Additionally, since we are aiming to see an increase 
in milk production with the use of metformin, we will monitor the number of wet diapers 
produced daily by each infant as well as keep track of how much feeding 
supplementation with formula is needed if the infant is unable to meet feeding 
requirements with breastmilk alone.   
2.5.5 Sample Size and Statistical Significance 
 
Previous studies have estimated a post-intervention increase of 30% vs 0% in the 
metformin vs placebo groups.49 The study conducted by Nommsen-Rivers et al is the 
only randomized controlled trial we know of that has used metformin as an intervention 
to increase breastmilk production but since their study was considered a pilot study this 
affected their sample size parameters. They selected 79% power with an alpha of 0.10 to 
detect a difference of 30%  in the volume of breastmilk produced from women taking 
metformin vs women taking the placebo.49 Additionally, they allocated participants 2:1 
(metformin:placebo) and in our study we will be allocating 1:1. We will take this study’s 
sample size calculation and estimation of effect size into consideration but due to the 
nature of our study we will select a power of 80% with an alpha of 0.05.   
2.6 Conclusion  
The literature review supports the need for a well-designed randomized controlled 
trial to determine the effect of metformin use during the postpartum period on breastmilk 
supply in women diagnosed with GDM. There are very limited existing studies that look 
at this relationship, especially with metformin use that continues from the third trimester 




as well as its efficacy in improving insulin sensitivity but its efficacy in improving milk 
production has not been sufficiently studied and is still unknown. The results of a 
randomized controlled trial could help to guide providers’ recommendations to women 
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CHAPTER 3: STUDY METHODS 
 
3.1 Study Design 
 
 We propose a two arm, double-blinded, parallel design, randomized controlled 
trial analyzing the effect of metformin use during the first eight weeks of the post-partum 
period on lactation in women who have been diagnosed with class A2 gestational 
diabetes mellitus (GDM).  
In this study, we plan to analyze the effects of metformin between two groups: the 
experimental group of women who will take the prescribed dose of metformin daily and 
the control group who will be receiving a placebo. Both groups will have received the 
standard of care management for pregnant women diagnosed with A2 GDM during 
pregnancy, including regular prenatal visits and metformin treatment which had been 
started during their third trimester after failed management of gestational diabetes with 
diet changes and exercise. The treatment with metformin will be continued for the 
experimental group and will be substituted for a placebo at the time of delivery for the 
control group. Patients and providers will be blinded as to which pill (placebo versus 
metformin) they are receiving. We will use the Prenatal Breastfeeding Self-Efficacy 
Scale (P-BSES) as an intake survey to characterize baseline breastfeeding confidence 
between both groups of participants prior to being discharged from the hospital 
(Appendix A). During the study, we will employ daily breastfeeding and pumping logs 







3.2 Study Population and Sampling 
 
 The study population under investigation is women with singleton pregnancies in 
the third trimester who are diagnosed with gestational diabetes mellitus. The study 
population will be seeking prenatal care at the Yale New Haven Health System 
(YNHHS), with selection for the study population derived from the pregnant women who 
were diagnosed with GDM. The study population will include pregnant women over 18 
years of age who were diagnosed with GDM and are being treated with metformin during 
the antenatal period. We will recruit participants from Yale Maternal Fetal Medicine 
Diabetes in Pregnancy Program at Long Wharf Medical Center which provides services 
for pregnant women diagnosed with GDM.  
Participants will be pregnant women who are (1)  ≥18 years of age, (2) at 24–36 
weeks of gestation, (3) have a singleton pregnancy,  (4) are planning to exclusively 
breastfeed their infant, (5) were able to read the information sheet and sign the consent 
form and (6) are planning to deliver within the Yale New Haven Health System. Prior to 
the study, women will be excluded from the study based on the following: (1) any of the 
following pre-existing health conditions as indicated in medical records: pre-gestational 
diabetes, chronic kidney disease, chronic liver disease including hepatitis, chronic 
hypertension on medication other than aspirin, and lupus (2) those who have had breast 
surgery (including single or double mastectomy and/or breast implants) (3) mothers with 
pre-gestational diabetes and (4) mothers diagnosed with gestational diabetes prior to 24 
weeks’ gestation.  
Inclusion Criteria Exclusion Criteria  




• At 24-36 weeks of gestation 
• Singleton pregnancy 
• Will exclusively breastfeed infant 
• Will deliver within the Yale New 
Haven Health System 
 
1. Pre-gestational diabetes 
2. Chronic kidney disease 
3. Chronic liver disease 
including hepatitis 
4. Chronic hypertension  
5. Lupus 
• Not planning on exclusively 
breastfeeding 
• Previous single or double 
mastectomy and/or breast implants  
• Gestational diabetes diagnosis 
before 24 weeks’ gestation 
Table 1: Inclusion and Exclusion Criteria 
3.3 Recruitment 
 
 Women who visit the Yale Maternal Fetal Medicine Diabetes in Pregnancy 
Program and are diagnosed with GDM and initiating treatment with metformin during the 
third trimester will be recruited for our study. We will exclude women who do not plan to 
deliver at YNHHS, as we will not have access to their delivery records. We plan to 
recruit women at their routine prenatal care visits occurring during the third trimester. If 
the woman has GDM at a prenatal visit and satisfies the remaining inclusion criteria, the 
patient will be informed of the study and consented by the research coordinator.  
 Women who would like to complete the study will read and sign the consent form 
(appendix B) to provide their informed, written consent to study participation. Once 
informed consent is obtained, women will be randomized in a 1:1 enrollment ratio to 
either the metformin group or the placebo group using an online randomization software 
and a block randomization scheme. Randomization will take place at the end of their 
third trimester (>37 weeks’ gestation) in order to ensure medication continuation 




medication from metformin during their prenatal care to help control their gestational 
diabetes.  
 After delivery all women in the trial will receive their medication through the 
investigational pharmacy, which will dispense metformin or a placebo pill designed to 
appear like metformin. The women will be instructed to not take any remaining pills of 
their own metformin following delivery. Both groups will take the pills for 8 weeks 
following delivery. The dosage of metformin will be 500mg daily.  
The total recruitment period will be 12 months, from August 1, 2020 to August 1, 
2021. The follow-up period will extend 8 weeks after each woman’s date of delivery.  
3.4 Subject Protection and Confidentiality  
 
 The Yale Institutional Review Board policy on research involving pregnant 
women and neonates is referenced in the consent form in Appendix B. The study will be 
conducted pending ethical review by the Human Investigation Committee (HIC) of Yale 
University School of Medicine and YNHHS. Written informed consent will be obtained 
from all participants prior to entry into the study at the patient’s prenatal visit during the 
third trimester (see Appendix B). Subjects under the age of 18 years-old will not be 
included in this study. Additionally, all research staff will be trained in HIPAA. Upon 
entry into the study, participants will receive a de-identified number for data collection 
and statistical analysis. All protected health information will be de-identified for the 
purposes of blinding and confidentiality in the data analysis phase of the study. A Yale-
encrypted computer with a password-protected Excel-based database will be used to 
maintain confidentiality and security of the data. Only co-investigators will have the 




database will only be accessed on hospital property or through secure VPN access. All 
associated paperwork will be stored in a locked file in a locked office.  
3.5 Study Variables and Measures 
 
3.5.1 Independent Variable 
 
 The independent variable in this study is metformin use during the postpartum 
period, which is operationalized in the experimental group by having participants receive 
metformin from the investigational drug pharmacy after delivery. The control group will 
be given a placebo tablet from the same pharmacy to take once daily starting at the time 
of delivery. The pills will be identical in appearance so patients and their providers are 
blinded to which group they are in. Participants will be asked to maintain a log of their 
medication compliance as well as make note of any side effects they might be 
experiencing. Participants will be given all doses of their medication upon discharge from 
the hospital (56 total pills). Will contact participants once per week to review their logs, 
discuss any questions and obtain a pill count to monitor compliance.  
3.5.2 Study Outcomes  
 
 The primary outcome of this study is breastmilk production. This will be 
measured using infant test weighs taken immediately before and after each feeding. We 
will ask participants to log these results in their breastfeeding logs which will be provided 
to them (Appendix C). Specialized scales will be provided for each participant to take 
home and use for the duration of the study to weight their infants. Prior to discharge from 
the hospital each mother will have the opportunity to meet with a lactation specialist to 
ensure that she is prepared and feels confident in her abilities to breastfeed once she 




weights and observe them conducting practice test weighs prior to discharge. Should they 
get home and have any questions we will provide them with a link to an instructional 
video of how to conduct these weighs. Each participant will receive a follow up calls 
once a week throughout the duration of the study in which they can ask any questions or 
concerns they might have, and we will ensure that they are properly conducting the test 
weighs.  
There are five secondary outcomes of interest that we will analyze: (1) onset of 
lactogenesis (2) infant weights at their routine pediatrician visits, (3) the need for feeding 
supplementation with formula, (4) number of wet diapers per day, and (5) maternal 
fasting glucose levels tested daily. Infant weights will also be checked at each follow up 
appointment which will occur at weeks 1,2, 4, and 8 of the study. We will ask each study 
participant to record the number of wet diapers and times that supplementation with 
formula was needed daily in the same log that they will be using to record their breast 
feedings (Appendix C). Participants will be instructed to take their own fasting blood 
glucose levels once daily upon waking in the morning for the day, prior to their first meal 
and keep a log of their results which will then be collected at the conclusion of the study. 
(Appendix D) 
Primary Outcome Secondary Outcomes 
• Breastmilk production as 
measured by pre and post feeding 
infant weights.  
• Time of onset of lactogenesis 
• Infant weights at their pediatrician 
visits 
• Frequency of feeding 
supplementation with formula 
• Number of wet diapers daily 
• Maternal fasting glucose levels  






3.5.3 Potential Confounding and Explanatory Variables 
 
 Development of GDM and subsequent low breastmilk supply is influenced by 
several covariates. Potential confounders include maternal age, maternal ethnicity, 
maternal education level achieved, maternal marital status, pre-pregnancy BMI, family 
history of GDM or type 2 diabetes, diagnosis of GDM in previous pregnancies, other 
signs of insulin resistance such as polycystic ovarian syndrome, number of previous 
breastfed infants, vaginal versus cesarean delivery, and parity. As participants will be 
randomized to their assigned group, we hope to minimize the effect of cofounding 
variables on the main outcome. We will also obtain this demographic and medical history 
data via an intake survey upon entry into the study (Appendix E) and through the 
participants’ charts and will compare these characteristics of the participants between 
assigned groups for any significant differences.  
3.6 Data Collection  
 
 Upon entry into the study, each participant will complete a Prenatal Breastfeeding 
Self-Efficacy Scale (P-BSES) to characterize their baseline breastfeeding confidence 
prior to being discharged from the hospital. Those who score less than 60 points on the 
scale or those who do not feel confident or adequately prepared will have an additional 
lactation consultation prior to discharge. The P-BSES is a 20-item scale designed to 
measure pregnant women’s self-efficacy for breastfeeding. The four factors comprising 
the scale assess confidence regarding 1) skills and demands for breastfeeding or 
pumping, 2) gathering information about breastfeeding, 3) breastfeeding around other 
people, and 4) social pressure when breastfeeding. There is evidence that the P-BSES has 




previous breastfeeding information and maternal education level from each participant 
using a questionnaire (Appendix E). Information on baseline characteristics, including 
maternal age, maternal ethnicity, pre-pregnancy weight, height, and BMI will all be 
obtained from participant’s electronic medical records.  
 In both groups, we will have participants log their daily feedings in a journal that 
will be given to them (Refer to Appendix C). This journal will also be used to input the 
test weighs before and after each feeding. We will ask participants to record the time of 
feeding, the duration of the feed, the type of feeding and if supplementation with formula 
was used. Additionally, we will have participants log the number of wet diapers per day. 
We will be evaluating the mother’s fasting blood glucose levels daily so we will ask the 
participants to take a fasting blood glucose every morning and to record these results 
(Appendix D).  
After discharge from delivery, we will ask to have the participants follow up at 
the Yale Pediatrics office at weeks 1, 2, 4, and 8. During these appointments we will 
perform all standard neonatal care as well as review the participant’s journal entries and 
record the infant’s weight.  
3.7 Sample Size Calculation  
 
  The main goal of the proposed study is to test the two-sided null hypothesis that 
metformin use during the postpartum period does not change the amount of breastmilk 
production. Sample size calculation is based on the primary outcome of breastmilk 
production. The aim is to observe an increase in the amount of breastmilk produced in the 
experimental group compared to the control group. Our calculation is based on previous 




hypothesis with a type 1 error of 1% and a power of 80%, a total sample size of 56 is 
required, or 28 in each arm. Due to the nature of the study and comparing median values 
versus means, we will add 15% to each group to compensate.  Additionally, we must 
account for 10% attrition rate. Therefore, our final sample size of will be 72 participants 
used in this study. Please see Appendix F for the full sample size calculation. 
3.8 Statistical Analysis   
 
Demographic information will be obtained for all participating women and will be 
analyzed for any statistically significant differences between groups (Refer to Table 3). 
Characteristics of interest that will be analyzed include maternal age, maternal ethnicity, 
maternal education level achieved, maternal marital status, pre-pregnancy BMI, family 
history of GDM or type 2 diabetes, diagnosis of GDM in previous pregnancies, other 
signs of insulin resistance such as polycystic ovarian syndrome, number of previous 
breastfed infants, vaginal versus cesarean delivery, and parity. Student t-test will be used 
for analysis of maternal age, as a continuous, parametric variable. Wilcoxon rank sum 
will be used to analyze ordinal variables such as maternal ethnicity, maternal marital 
status, and maternal BMI, as well as non-parametric continuous variables such as parity. 
A chi square test will be used to analyze proportions between groups for ethnicity and 
previous diagnosis of GDM. Lastly, we will analyze educational level (measured by 
mean years) with ANOVA. Multivariate analysis using logistic regression will be utilized 














     18-24 years 
     25-30 years 
     30-35 years 
      ≥35 years 
   
Ethnicity 
     Non-Hispanic White 
     Black 
     Hispanic 
     Asian 
     Other  
   
Marital Status 
     Married 
     Single 
Other Forms of Insulin 
Resistance  
     Yes 
     No 
Family History of GDM 
     Yes 
     No 
Family History of Type 2 DM 
     Yes 
     No 
Diagnosis of GDM in 
Previous Pregnancy 
     Yes 
     No 
Parity  
     0 
     1 
     2 
     >3 
Number of Previous 
Breastfed Infants 
     0 
     1  
     2 
     >3 
   
Type of Delivery 
     Vaginal 
     Cesarean 





    19.8-25.9 
    26.0-28.9 
    29.0-34.9 
    ≥35.0 
   
 Mean (SD) Mean (SD)  
Education (years)    
Table 3: Baseline Characteristics of Study Population  
3.9 Timeline and Resources 
 
Pending Institutional Review Board (IRB) approval, we will begin recruiting 
pregnant women for 12 months; all mothers must deliver within the first 18 months and 
follow up will last for 2 months following time of delivery. All data will be collected 
within a 2-year timespan. We will then require one month to run and interpret results and 
an additional month to write and report our findings. Proposed study personnel include: 
one principal investigator to oversee all operations, one physician trained in obstetrics to 
assess participant’s charts for diagnosis of A2GDM, one Physician Assistant student for 
data organization, statistical analysis and writing, and one trained research assistant for 
recruitment and intake.  
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CHAPTER 4: CONCLUSION 
 
4.1 Advantages and Disadvantages 
 
It is well documented that women who are diagnosed with gestational diabetes 
mellitus have worse breastfeeding outcomes than their counterparts. Specifically, women 
with GDM have much lower exclusive breastfeeding rates and shorter durations of 
breastfeeding.1,2 Unfortunately, up to this point there have not been any studies looking at 
effective interventions to improve breastfeeding rates in this population. Therefore, there 
is a need for a large randomized controlled trial to examine the use of an existing 
therapeutic agent used in treating gestational diabetes and determine if there is a causal 
relationship between metformin use during the postpartum period and increased 
breastmilk supply. This study addresses the paucity in the current literature and has the 
potential to change current practice guidelines.  
 The proposed study has both its strengths and limitations. A major strength of our 
study is its feasibility and practicality. The intervention requires little time commitment 
from participants and is easy to implement. Metformin, in comparison to insulin, has 
been found to be viewed favorably by patients due to its oral route of administration, low 
cost, easy dose titration, and low risk of hypoglycemia.3 Also, study participants will 
have been on metformin prior to delivery so they will already be used to the medication 
and will be less likely to experience side effects throughout the duration of the study. All 
of these are factors that will aid in achieving high medication compliance with 
participants. Additionally, the intervention is low-cost since all required medications and 




as follow-up visits will be completed at set time intervals and phone call follow-ups will 
be implemented weekly throughout the duration of the study to answer any questions or 
concerns participants might have. Therefore, we anticipate strong internal validity and 
minimal response bias in this study. However, by limiting our study to the Yale New 
Haven Health System we may limit our external validity and generalizability. Despite 
limiting recruitment to the Yale New Haven Health System, we will strive to recruit a 
diverse group of participants. 
The main advantage of this study is its randomized, prospective design that allows 
for the observation of a causal relationship between metformin treatment and breastmilk 
production in women diagnosed with GDM. It is the only randomized controlled trial that 
tests the effect of continuing metformin treatment into the postpartum period on the 
production of breastmilk in women with a diagnosis of GDM. By conducting an RCT and 
randomizing patients 1:1 to the intervention and control groups, we hope to decrease 
selection bias and confounders. Furthermore, our proposed study will be double blinded 
which we hope will aid in limiting outcome reporting bias. 
When considering the timeline for the study we realize that an eight-weeklong 
duration may limit our understanding of long-term effects of metformin on breast milk 
production. However, we feel that a longer intervention duration would decrease patient 
adherence. Since we know that metformin typically begins to improve blood sugar 
control within a week3,4 we feel as though eight weeks is a sufficient amount of time to 
get an understanding of what effects metformin might have. We know that studies similar 




hope that continuing our study for an additional four weeks will be an advantage and give 
additional insight into our research question and place emphasis on the importance of 
continued breastfeeding beyond the initial postpartum period.  
4.2 Clinical and Public Health Significance 
 
In all of the previous studies addressing the different therapeutic options for 
diabetes during pregnancy, several neonatal and maternal outcomes have been analyzed 
and studied but one factor that hasn’t been studied in depth is the effect on breast milk 
production and lactogenesis. This is a long-term factor that can have an impact on 
infancy and childhood for many neonates and it is an important factor to identify and 
study in correlation with metformin therapy.  
This is an important problem to find a solution to because currently 23% of 
reproductive aged women in the United States are prediabetic and 8.2% of women are 
diagnosed with gestational diabetes; therefore, this could be an unrealized impediment to 
raising breastfeeding rates and breastfeeding duration in the US.6 Finding a way to 
increase the postpartum milk production in women diagnosed with GDM could aid in 
longer compliance with breastfeeding. This is important because it has been proven that 
continued breastfeeding for more than six months lowers the chances of childhood and 
adult illnesses and, if the child does get ill, can help the child in recovering more 
quickly.7 It has also been shown that longer breastfeeding duration lessens the child’s 
chances of developing type 1 and type 2 diabetes as well as obesity.8 Breastfeeding is not 
only beneficial for infants but also for mothers, by continuing breastfeeding beyond six 
months, it can lower the lifelong risk of developing heart disease,9 type 2 diabetes10 and 




to find a targeted therapy that can support lactation success in women who have glucose 
intolerance.    
Our hope is that this proposed study would address an important question that has 
not yet been addressed in the literature. The findings of this study will provide insight 
into breastfeeding rates and success in women with A2GDM.  
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Appendix A: Infant Feeding Intentions Scale 
 
Please read the following statements and answer circling the number closest to your 
feelings. It is important to know (remember) that there is no right or wrong answer 
in answering these questions. We are interested in how much you are relyed of 
yourself about your breastfeeding. 
 
1: I am definitely not confident 2: I am not quite confident 3: I am confident4: I am very confident 5: 




1. I can find the answers to problems I may encounter while 
breastfeeding my baby.  
1 2 3 4 5 
2. I can find the information I need about breastfeeding my 
baby.  
1 2 3 4 5 
3. If I have questions about breastfeeding my baby, I know 
whom I can ask. 
1 2 3 4 5 
4. I can talk about the importance of breastfeeding my baby 
with my husband. 
1 2 3 4 5 
5. I can talk about breastfeeding my baby with health workers.  1 2 3 4 5 
6. I can organize my day according to the times I need to 
breastfeed my baby.  
1 2 3 4 5 
7. I can find time for breastfeeding my baby even if I am busy. 1 2 3 4 5 
8. I can breastfeed my baby even when I am tired.  1 2 3 4 5 
9. I can breastfeed my baby even when I am feeling 
depressed.  
1 2 3 4 5 
10. I can draw milk manually or through use of a breast pump. 1 2 3 4 5 
11. I can milk my breast and prepare my milk for someone else 
to feed my baby.  
1 2 3 4 5 
12. I can breastfeed my baby even if it causes a little discomfort.  1 2 3 4 5 
13. I can breastfeed my baby without any feelings of shame.  1 2 3 4 5 
14. I can breastfeed my baby while my husband is present.  1 2 3 4 5 
15. I can breastfeed my baby while my family or friends are present.  1 2 3 4 5 
16. I can breastfeed my baby even when people I do not know are 
present.  
1 2 3 4 5 
17. I can call a breastfeeding consultant when I have problems with 
breastfeeding.  
1 2 3 4 5 
18. I would breastfeed my baby even if my husband did not want me 
to do it.  
1 2 3 4 5 
19. I would breastfeed my baby even my family did not want me to 
do it.  
1 2 3 4 5 




Appendix B: Human Investigations Committee Consent Form 
 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN 
HOSPITAL 
 
Study Title: Randomized Study of Postpartum Metformin Use to Augment Breastmilk 
Supply  
Principal Investigator: Audrey Merriam, MD 
Co-Principal Investigator: Meghan Sowers, PA-SII 
 
Invitation to Participate and Description of Project 
 
You are invited to participate in a research study designed to look at the effects of 
continuing metformin treatment into the postpartum period and its effects on breastmilk 
supply in women with gestational diabetes. If you are reading this consent form, you have 
been selected for recruitment in this study during your pregnancy. You were selected for 
potential recruitment in this study, because you are currently pregnant and have gestational 
diabetes mellitus which is currently being treated with metformin. Gestational diabetes is 
a condition that only affects pregnant women and causes high blood sugar levels. This 
condition can have many effects on mothers and babies, one of them being delayed 
lactogenesis, when milk production starts, as well as decreased milk production resulting 
in lower breastfeeding rates. This study will take place within the Yale New Haven Health 
System over the next two years.  
 
In order to decide whether or not you wish to be a part of this research study, you should 
know enough about its risks and benefits to make an informed decision.  This consent form 
gives you detailed information about the research study, which a member of the research 
team will discuss with you.  This discussion should go over all aspects of this research: its 
purpose, the procedures that will be performed, any risks of the procedures, possible 
benefits and possible alternative treatments. Once you understand the study, you will be 
asked if you wish to participate; if so, you will be asked to sign this form. 
 
Description of Procedures 
 
If you agree to participate in this study, you will be randomly assigned to one of two 
groups, either the metformin group or the placebo group. An online software will be used 
to assign all participants randomly into one of the two groups.  
If you are assigned to the metformin group, you will be instructed to take metformin 
daily. This will start at the time of delivery and will continue for eight weeks postpartum. 
You will also be given a journal to record your feedings as well as other variables that we 
would like to collect data on. Additionally, we will ask participants to check their blood 




If you are assigned to the placebo group, you will be instructed to take one placebo tablet 
daily. This will start at the time of delivery and will continue for eight weeks postpartum. 
You will also be given a journal to record your feedings as well as other variables that we 
would like to collect data on. Additionally, we will ask participants to check their blood 
sugar levels daily and record these findings.  
After you give birth, our research team will contact you and give you instructions as to 
what to do going forward. We will additionally gather data from your medical chart such 
as demographic information (i.e. age, race), past medical history (e.g. number of previous 
pregnancies, health complications) weight, gestational age at delivery, whether or not you 
had a Cesarean section (and if so, why), assessment of your baby, and any complications 
that may have occurred during labor or birth. This information will help us determine if 
there is any difference in outcomes between the groups.  
 
You will be told of any significant new findings that develop during the course of your 
participation in this study that may affect your willingness to continue to participate. 
 





Any identifiable information that is obtained in connection with this study will remain 
confidential and will be disclosed only with your permission or as required by U.S. or State 
law. Examples of information that we are legally required to disclose include abuse of a 
child or elderly person, or certain reportable diseases. When the results of the research are 
published or discussed in conferences, no information will be included that would reveal 
your identity unless your specific consent for this activity is obtained.   
 
Representatives from the Yale Human Research Protection Program, the Yale Human 
Investigation Committee (the committee that reviews, approves, and monitors research on 
human subjects) may inspect study records during internal auditing procedures.  However, 
these individuals are required to keep all information confidential.  
 
Voluntary Participation and Withdrawal 
 
Participating in this study is voluntary. You are free to choose not to take part in this 
study. Refusing to participate will involve no penalty or loss of benefits to which you are 
otherwise entitled (such as your healthcare outside of the study, the payment for your 
healthcare, or your healthcare benefits).  However, you will not be able to enroll in this 
research study and will not receive study procedures as a study participant if you do not 
allow use of your information as part of this study. If you do become a subject, you are 
free to stop and withdraw from this study at any time during its course.  
 
To withdraw from the study, you can call a member of the research team at any time and 




participating in the research if necessary. This may occur if your obstetrician feels it is 
medically unsafe to proceed with the intervention to which you have been allocated.  
 
Withdrawing from the study will involve no penalty or loss of benefits to which you are 
otherwise entitled.  It will not harm your relationship with your own doctors. 
 
When you withdraw from the study, no new health information identifying you will be 
gathered after that date.  Information that has already been gathered may still be used and 
given to others until the end of the research study, as necessary to ensure the integrity of 
the study and/or study oversight.   
 




We have used some technical terms in this form.  Please feel free to ask about anything 
you don't understand and to consider this research and the consent form carefully – as long 







I have read (or someone has read to me) this form and have decided to participate in the 
project described above.  Its general purposes, the particulars of my involvement and 
possible hazards and inconveniences have been explained to my satisfaction.  My signature 














___________________________________________          ___________________ 
Signature of Principal Investigator  Date 
  
                                      or 
 
___________________________________________ ___________________ 
Signature of Person Obtaining Consent  Date 
 
 
If you have further questions about this project or if you have a research-related problem, 
you may contact the Principal Investigator, Dr. Audrey Merriam. If, after you have 
signed this form you have any questions about your privacy rights, please contact the 
Yale Privacy Officer at 203-432-5919. If you would like to talk with someone other than 
the researchers to discuss problems, concerns, and questions you may have concerning 
this research, or to discuss your rights as a research subject, you may contact the Yale 








































          
          
          
          
          
          
          
          


















Day/Date Time Fasting? Y or N Blood Sugar 
Reading   
Did you take 
your 
medication 
today? Y or N 
Notes 
      
      
      
      
      
      
      
      
      
      
      




Appendix E: Baseline Intake Form 
 
 
Patient Information Form 
Please fill out this form to the best of your ability.  
 
1. What is your marital status? (Circle one)   
Married       Single        
2. Do you have a family history of gestational diabetes mellitus?     Yes        No 
3. Do you have a family history of type 2 diabetes?    Yes      No  
4. Have you ever been pregnant before?     Yes      No 
a. If “yes” how many times? _________ 
b. If “yes” were you ever diagnosed with gestational diabetes during any of 
your previous pregnancies?    Yes      No 
c. If “yes” did you breastfeed?    Yes     No 
5. Approximately how many years did you attend school (including high school, 












Appendix F: Sample Size Calculation 
 
Input: Tail(s): Two 
Power, 1 - β = 0.80 
Type I error rate, α = 1%  
Median increase in primary outcome, 8mL/24hr 
Sample Size: 56 (28 per group) 
 
Compensation for comparing medians, 15% to each group, 56 x 1.15=64.4 participants 
Estimated attrition rate, 10%, 65 x 1.10= 71.5 participants 
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